Search - tctmd.com

Displaying 1 - 20 of 47

Sort: Relevancy | Date

TCTMD’s Top 10 Most Popular Stories for December 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2023

December 28, 2023

AHA Selects 2023’s Leading Cardiovascular Research

News Daily News

AHA Selects 2023’s Leading Cardiovascular Research

December 22, 2023

Who Benefits Most From Semaglutide and How Long Will That Take?

News Daily News

Who Benefits Most From Semaglutide and How Long Will That Take?

December 19, 2023

Stopping Tirzepatide Leads to Rebound in Weight, Cardiometabolic Risk

News Daily News

Stopping Tirzepatide Leads to Rebound in Weight, Cardiometabolic Risk

December 12, 2023

Oral GLP-1 Drug Danuglipron to Move Forward, but With Tweaks to Dose

News Daily News

Oral GLP-1 Drug Danuglipron to Move Forward, but With Tweaks to Dose

December 01, 2023

‘Smoldering Epidemic’ of CVD Risk Factors in Middle-Aged Adults

News Daily News

‘Smoldering Epidemic’ of CVD Risk Factors in Middle-Aged Adults

Michael O'Riordan

November 21, 2023

Mortality Risk Varies Among Patients With Very High LDL Levels

News Daily News

Mortality Risk Varies Among Patients With Very High LDL Levels

Michael O'Riordan

November 17, 2023

New CVD Risk Tool Can Spur Even Earlier Talk About Prevention

News Conference News AHA 2023

New CVD Risk Tool Can Spur Even Earlier Talk About Prevention

Yael L. Maxwell

November 14, 2023

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

News Conference News AHA 2023

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

November 11, 2023

FDA Grants Tirzepatide a New Indication for Obesity Management

News Daily News

FDA Grants Tirzepatide a New Indication for Obesity Management

November 08, 2023

Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis

News Conference News HFSA 2023

Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis

October 11, 2023

Diabetes in Middle Age Linked to Earlier CVD Risk: Danish Study

News Daily News

Diabetes in Middle Age Linked to Earlier CVD Risk: Danish Study

October 10, 2023

Major GI Events Rare but Real in Weight-Loss Patients on GLP-1 Drugs

News Daily News

Major GI Events Rare but Real in Weight-Loss Patients on GLP-1 Drugs

October 06, 2023

PET-Guided Strategy Lowers Risk, Boosts Outcomes in Stable CAD: CENTURY

News Daily News

PET-Guided Strategy Lowers Risk, Boosts Outcomes in Stable CAD: CENTURY

Michael O'Riordan

September 29, 2023

GLP-1 Meds Linked to 265 Reports to FDA of Suicidal Ideation: Reuters

News Daily News

GLP-1 Meds Linked to 265 Reports to FDA of Suicidal Ideation: Reuters

September 28, 2023

European Regulators Investigating CV Safety of Weight-Loss Drug Mysimba

News Daily News

European Regulators Investigating CV Safety of Weight-Loss Drug Mysimba

Michael O'Riordan

September 15, 2023

Lorundrostat, an Aldosterone Synthase Inhibitor, Passes Phase II Hurdle

News Daily News

Lorundrostat, an Aldosterone Synthase Inhibitor, Passes Phase II Hurdle

September 12, 2023

Mortality, CVD Benefits Seen at Relatively Low Daily Step Counts

News Daily News

Mortality, CVD Benefits Seen at Relatively Low Daily Step Counts

Michael O'Riordan

September 08, 2023

STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function

News Conference News ESC 2023

STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function

August 25, 2023

A Mix of Aerobic and Strength Exercise Is Best for Boosting Survival

News Daily News

A Mix of Aerobic and Strength Exercise Is Best for Boosting Survival

August 09, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.